Nathalie Couque

Dr. Nathalie Couque

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 October 2019 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
VBValentine Brousse
Valentine Brousse
CACécile Arnaud
Cécile Arnaud
ELEmmanuelle Lesprit
Emmanuelle Lesprit
BQBéatrice Quinet
Béatrice Quinet
MOMarie-Hélène Odièvre
Marie-Hélène Odièvre
ITIsabelle Thuret
Isabelle Thuret
This study’s objective was to assess, on a national scale, residual risks of death, major disease-related events, and quality of care during the first five years in children diagnosed at birth with sickle cell disease (SCD). Data were retrospectively collected from medical files of all children with SCD born between 2006–2010 in France. Out of 1792 eligible subjects, 1620 patients (71.8% SS or S/beta°-thalassemia -SB°-) had available follow-up data, across 69 centers. Overall probability of survival by five years was 98.9%, with 12/18 deaths related to SCD. Probability of overt stroke by five years in SS/SB° patients was 1.1%, while transcranial Doppler (TCD) was performed in 81% before three years of age. A total of 26 patients had meningitis/septicemia (pneumococcal in eight cases). Prophylactic penicillin was started at a median age of 2.2 months and 87% of children had received appropriate conjugate pneumococcal vaccination at one year. By five years, the probability of survival without SCD-related events was 10.7% for SS/SB° patients. In contrast, hydroxyurea was prescribed in 13.7% and bone marrow transplant performed in nine patients only. In this study, residual risks of severe complications were low, probably resulting from a good national TCD, vaccination, and healthcare system coverage. Nonetheless, burden of disease remained high, stressing the need for disease-modifying or curative therapy.

29 May 2023 in Genes
Verified
Journal Article
Open access
PDF file
APAlejandro Parra
Alejandro Parra
RRRachel Rabin
Rachel Rabin
JPJohn Pappas
John Pappas
PPPatricia Pascual
Patricia Pascual
MCMario Cazalla
Mario Cazalla
PLPablo Lapunzina
Pablo Lapunzina
SETD2 belongs to the family of histone methyltransferase proteins and has been associated with three nosologically distinct entities with different clinical and molecular features: Luscan–Lumish syndrome (LLS), intellectual developmental disorder, autosomal dominant 70 (MRD70), and Rabin–Pappas syndrome (RAPAS). LLS [MIM #616831] is an overgrowth disorder with multisystem involvement including intellectual disability, speech delay, autism spectrum disorder (ASD), macrocephaly, tall stature, and motor delay. RAPAS [MIM #6201551] is a recently reported multisystemic disorder characterized by severely impaired global and intellectual development, hypotonia, feeding difficulties with failure to thrive, microcephaly, and dysmorphic facial features. Other neurologic findings may include seizures, hearing loss, ophthalmologic defects, and brain imaging abnormalities. There is variable involvement of other organ systems, including skeletal, genitourinary, cardiac, and potentially endocrine. Three patients who carried the missense variant p.Arg1740Gln in SETD2 were reported with a moderately impaired intellectual disability, speech difficulties, and behavioral abnormalities. More variable findings included hypotonia and dysmorphic features. Due to the differences with the two previous phenotypes, this association was then named intellectual developmental disorder, autosomal dominant 70 [MIM 620157]. These three disorders seem to be allelic and are caused either by loss-of-function, gain-of-function, or missense variants in the SETD2 gene. Here we describe 18 new patients with variants in SETD2, most of them with the LLS phenotype, and reviewed 33 additional patients with variants in SETD2 that have been previously reported in the scientific literature. This article offers an expansion of the number of reported individuals with LLS and highlights the clinical features and the similarities and differences among the three phenotypes associated with SETD2.

21 May 2018 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
BABichr Allaf
Bichr Allaf
FPFranck Patin
Franck Patin
Jacques ElionJacques Elion
Jacques Elion
NCNathalie Couque
Nathalie Couque

27 June 2021 in Clinical Genetics
Verified
Journal Article
Closed access
PDF file
JLJonathan Levy
Jonathan Levy
BSBérénice Schell
Bérénice Schell
HNHala Nasser
Hala Nasser
MRMyriam Rachid
Myriam Rachid
LRLyse Ruaud
Lyse Ruaud
ATAnne‐Claude Tabet
Anne‐Claude Tabet

10 February 2024 in European Journal of Medical Genetics
Verified
Journal Article
Open access
LMLottie D. Morison
Lottie D. Morison
OROlivia Van Reyk
Olivia Van Reyk
EBEmma Baker
Emma Baker
LRLyse Ruaud
Lyse Ruaud
NCNathalie Couque
Nathalie Couque
AMAngela T. Morgan
Angela T. Morgan
Pathogenic variants in BRPF1 cause intellectual disability, ptosis and facial dysmorphism. Speech and language deficits have been identified as a manifestation of BRPF1-related disorder but have not been systematically characterized. We provide a comprehensive delineation of speech and language abilities in BRPF1-related disorder and expand the phenotype. Speech and language, and health and medical history were assessed in 15 participants (male = 10, median age = 7 years 4 months) with 14 BRPF1 variants. Language disorders were common (11/12), and most had mild to moderate deficits across receptive, expressive, written, and social-pragmatic domains. Speech disorders were frequent (7/9), including phonological delay (6/9) and disorder (3/9), and childhood apraxia of speech (3/9). All those tested for cognitive abilities had a FSIQ ≥70 (4/4). Participants had vision impairment (13/15), fine (8/15) and gross motor delay (10/15) which often resolved in later childhood, infant feeding impairment (8/15), and infant hypotonia (9/15). We have implicated BRPF1-related disorder as causative for speech and language disorder, including childhood apraxia of speech. Adaptive behavior and cognition were strengths when compared to other monogenic neurodevelopmental chromatin-related disorders. The universal involvement of speech and language impairment is noteable, relative to the high degree of phenotypic variability in BRPF1-related disorder.

1 April 2016 in Revue Francophone des Laboratoires
Verified
Journal Article
Closed access
NCNathalie Couque
Nathalie Couque
ETElisabeth Trawinski
Elisabeth Trawinski
Jacques ElionJacques Elion
Jacques Elion